Comparative Pharmacology
Head-to-head clinical analysis: BREO ELLIPTA versus XENEISOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREO ELLIPTA versus XENEISOL.
BREO ELLIPTA vs XENEISOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.
XENEISOL is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the synaptic cleft.
One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.
10 mg orally once daily, titrated to a maximum of 20 mg daily based on response and tolerability.
None Documented
None Documented
Fluticasone furoate: 24 hours (supports once-daily dosing). Vilanterol: 11 hours (supports once-daily dosing).
Terminal elimination half-life is 4.5 hours (range 3.5-6 hours) in adults; prolonged to 8-12 hours in hepatic impairment.
Fluticasone furoate is eliminated primarily via fecal excretion (approximately 101% of an oral dose) due to biliary clearance, with minimal renal excretion (<1%). Vilanterol is eliminated via metabolism and subsequent renal (approximately 70% of an IV dose) and fecal (approximately 30% of an IV dose) excretion.
Primarily hepatic metabolism followed by renal excretion of metabolites: 70% renal, 20% biliary/fecal, 10% unchanged in urine.
Category C
Category C
Corticosteroid/Beta-2 Agonist Combination
Corticosteroid